In addition, genetic ablation or pharmacological inactivation of Skp2 re-sensitizes the gefitinib-resistant NSCLC cells toward gefitinib treatment, improving the potential of Skp2 targeting to overcome gefitinib resistance in NSCLS patients22. The gene discussed is SKP2; the disease is non-small cell lung carcinoma.